ABN Amro Investment Solutions Has $2.08 Million Stock Holdings in Edwards Lifesciences Corporation $EW

ABN Amro Investment Solutions increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 361.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,419 shares of the medical research company’s stock after purchasing an additional 19,123 shares during the quarter. ABN Amro Investment Solutions’ holdings in Edwards Lifesciences were worth $2,082,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter worth approximately $25,000. Kohmann Bosshard Financial Services LLC acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its position in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Dorato Capital Management bought a new stake in Edwards Lifesciences during the fourth quarter worth $29,000. Finally, Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,968 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $82.07, for a total value of $818,073.76. Following the sale, the vice president directly owned 22,798 shares of the company’s stock, valued at $1,871,031.86. This trade represents a 30.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 106,684 shares of company stock worth $8,811,739 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 3.3%

Shares of Edwards Lifesciences stock opened at $85.93 on Friday. The stock has a fifty day simple moving average of $81.42 and a 200 day simple moving average of $82.89. The company has a market capitalization of $49.48 billion, a P/E ratio of 45.71, a price-to-earnings-growth ratio of 2.09 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.